4588.T
Oncolys BioPharma Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 7,400.00
−6.33%Year over year
Reported trailing growth
- Revenue
- -9.7%
- EBITDA
- —
- EBIT
- -20.4%
- EPS
- -1.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +3471.4%
- EBITDA
- —
- EPS
- -15.2%
Three-year CAGR
- Revenue
- -69.4%
- EBITDA
- -20.4%
- EBIT
- -20.4%
- Net income
- -22.2%
- EPS
- -3.7%
- Free cash flow
- +4.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026